PCCTC Trial Is First to Use Standard Ra-223 Doses, Contemporary Pain Endpoints and PRO Collection Tools
Study published in Clinical Genitourinary Cancer details the first examining radium-223 in pain palliation using standard doses and contemporary pain end points radium-223, and demonstrated radium-223’s ability to palliate pain in a clinically meaningful manner in nearly one-half of enrolled patients.
Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry
The Diversity Working Group of the IRONMAN registry has developed informed strategies for site selection, recruitment, engagement and retention, and trial design and eligibility criteria to ensure broad inclusion and needs awareness of minority participants.
The PCCTC Germline Genetics Working Group Publishes New Guidelines
Manuscript published in JCO Oncology Practice details practical considerations and challenges for germline genetic testing in patients with prostate cancer
PCCTC Investigators on the Diversity of Enrollment in Prostate Cancer Clinical Trials
Despite known racial disparities, men of color remain underrepresented in prostate cancer clinical trials
The Transformative Development and Progress of the PCCTC
Dr Charles Ryan is joined by the leadership of the Prostate Cancer Clinical Trials Consortium, a group that has developed innumerable trials and therapies for advanced prostate cancer.
CellCentric Signs Agreement with the PCCTC for Phase II Clinical Trial Expansion Into the US
CellCentric has signed an agreement with the PCCTC to help select and manage US sites for the ongoing evaluation of CCS1477.